William Canfield

Who is William Canfield?

William Canfield is a glycobiologist, chief scientific officer and founder of an Oklahoma City-based biotechnology company, Novazyme, which was acquired by Genzyme in August 2001 and developed, among other things, an enzyme that can stabilize Pompe disease, based on Canfield's ongoing research since 1998. Canfield subsequently left Genzyme and established, with his partner in the Novazyme operation, John Crowley, another research laboratory, which he still heads. He saved Cytovance from bankruptcy by forming an investor group and raising $9 million after Crowley suddenly left the lab in 2005 to become the chief executive officer at Amicus Therapeutics in New Jersey